 Home > Active Ingredient News > Antitumor Therapy > Eur Heart J: Analysis of re-admission of cancer patients treated with percutaneous coronary intervention due to acute myocardial infarction and bleeding within 90 days

Eur Heart J: Analysis of re-admission of cancer patients treated with percutaneous coronary intervention due to acute myocardial infarction and bleeding within 90 days

 Last Update: 2021-03-20
 Source: Internet
 Author: User

Tags

cholesterol turkey breast

buy 2 4

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The post-discharge outcome of cancer patients undergoing percutaneous coronary intervention (PCI) is not yet clear.

Recently, the medsci.

medsci.

Between 2010 and 2014, researchers included patients who received PCI in the US admissions database to evaluate the impact of cancer on AMI and bleeding after 90-day hospitalization.

A total of 1,933,324 patients were included in the study (2.

Breast cancer colon cancer

It can be seen that after PCI, cancer patients are at increased risk of re-admission due to AMI or bleeding.

After PCI, cancer patients are at increased risk of re-admission due to AMI or bleeding.

Original source:

Chun Shing Kwok,et al.

org/10.
1093/eurheartj/ehaa1032" target="_blank" rel="noopener">Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.